FDA's OxyContin Ruling May Spur New Battles Over Generics

Law360, New York (April 23, 2013, 2:54 PM EDT) -- Last week's decision by the U.S. Food and Drug Administration to block generic versions of the oft-abused painkiller OxyContin could embolden makers of other top-selling branded drugs to push the agency to grant them what amounts to a major patent extension by citing safety concerns, drug industry experts say.

Last week, the FDA announced that it would not accept any generic applications based on the original version of Purdue Pharma LP's OxyContin, an opioid painkiller, the same day the patent expired. The agency said it found...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.